| Mrs Deborah Lynn Mccoy, FNP | |
|
7702 Central Park Dr, Waco, TX 76712-6535 | |
| (254) 202-7700 | |
| (254) 202-7710 |
| Full Name | Mrs Deborah Lynn Mccoy |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 25 Years |
| Location | 7702 Central Park Dr, Waco, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285608372 | NPI | - | NPPES |
| 41484901 | Medicaid | TX | |
| 86N749 | Other | TX | BC BS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Interim Healthcare Of Waco | Woodway, TX | Home health agency |
| Baylor Scott & White Medical Center Hillcrest | Waco, TX | Hospital |
| Providence Health Center | Waco, TX | Hospital |
| Baylor Scott & White Pavilion - Temple | Temple, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hillcrest Family Health Center | 4183612278 | 55 |
News Archive
Cancer metastasis – the spread of disease from the original site to a distant organ – remains a major challenge in treating cancer and a main cause of morbidity and mortality.
Major disparities exist along racial and ethnic lines in the United States for various medical conditions, but guidance is scarce about how to reduce these gaps. Now, a new "roadmap" has been unveiled to give organizations expert guidance on how to improve health equity in their own patient populations.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
/news/20200113/Research-could-help-explain-why-some-people-use-marijuana-when-stressed-or-anxious.aspx
› Verified 9 days ago
| Entity Name | Hillcrest Family Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891796694 PECOS PAC ID: 4183612278 Enrollment ID: O20040505001729 |
News Archive
Cancer metastasis – the spread of disease from the original site to a distant organ – remains a major challenge in treating cancer and a main cause of morbidity and mortality.
Major disparities exist along racial and ethnic lines in the United States for various medical conditions, but guidance is scarce about how to reduce these gaps. Now, a new "roadmap" has been unveiled to give organizations expert guidance on how to improve health equity in their own patient populations.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
/news/20200113/Research-could-help-explain-why-some-people-use-marijuana-when-stressed-or-anxious.aspx
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Deborah Lynn Mccoy, FNP Po Box 848476, Dallas, TX 75284-8476 Ph: (254) 202-4655 | Mrs Deborah Lynn Mccoy, FNP 7702 Central Park Dr, Waco, TX 76712-6535 Ph: (254) 202-7700 |
News Archive
Cancer metastasis – the spread of disease from the original site to a distant organ – remains a major challenge in treating cancer and a main cause of morbidity and mortality.
Major disparities exist along racial and ethnic lines in the United States for various medical conditions, but guidance is scarce about how to reduce these gaps. Now, a new "roadmap" has been unveiled to give organizations expert guidance on how to improve health equity in their own patient populations.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
/news/20200113/Research-could-help-explain-why-some-people-use-marijuana-when-stressed-or-anxious.aspx
› Verified 9 days ago